What stands out for senior leaders
We selected Mesoblast Limited for its focus on developing cell therapies for severe inflammatory diseases. In our judgement, that mission gives senior leaders a clear reason to examine the company: its product focus is directly connected to serious medical need.
Founded in 2004 and led by Dr Silviu Itescu, Mesoblast is publicly listed, with revenue of US$120.3M in FY2026. These facts give substance to the profile, although they do not, on their own, establish growth or clinical outcomes.
Its offices in Melbourne, New York and Singapore sit alongside a headcount band of 100–250. We see an international footprint within a relatively compact organisation, making it worth exploring for leaders interested in the intersection of biotechnology, strategy and public-market accountability.
Leadership areas
- Operations & Strategy
- Finance & Capital
- Legal, Risk & Governance
The honest trade-off
Mesoblast may not suit leaders who prefer a privately held company rather than a publicly listed business. Its specialised focus on cell therapies may also be less aligned with those seeking a broader product remit outside health and biotechnology.
Questions leaders ask about Mesoblast Limited
- What does Mesoblast Limited focus on?
- Mesoblast operates in health and biotechnology, with a mission to develop cell therapies for severe inflammatory diseases.
- Who leads Mesoblast Limited?
- Mesoblast's CEO is Dr Silviu Itescu. The company was founded in 2004.
- Where does Mesoblast have offices, and what is its scale?
- Mesoblast has offices in Melbourne, New York and Singapore, with a headcount band of 100–250. It is publicly listed and recorded revenue of US$120.3M in FY2026.
Sources
Last checked November 2026








